Nervous Disorder TRIZ Cases

Multimeric Fc constructs combine multiple domains to extend serum circulation time, resolving the trade-off between duration of action and binding affinity.

Nitroxide spin-labeled compounds bind to amyloid beta peptides, providing specific MRI contrast without relying on endogenous iron levels.

A microneedle system delivers interferon using a polyvinylpyrrolidone formulation.

Combining anticonvulsants, neurosteroids, NK-1 antagonists, and lithium compounds addresses formulation complexity while preventing neuropathology.

Amnion-derived multipotent progenitor cells address limited therapeutic success by secreting neurotrophic factors that stimulate endogenous repair mechanisms.

Bicyclic [4,6,0] hydroxamic acids target HDAC6 to improve therapeutic effectiveness while reducing side effects associated with existing treatments.

CRISPR-Cas9 editing targets mutant Huntingtin alleles via single nucleotide polymorphisms, reducing disease-causing protein while preserving wild-type function.

Segmented genetic screening identifies progranulin mutations while targeted agents increase protein levels to delay neurodegenerative disorder progression.

Segmented sequencing of TOMM40 and ApoE genes resolves the trade-off between prediction accuracy and analysis complexity for early Alzheimer's intervention.

Non-aqueous solvent prevents active component aggregation during rapid mixing, ensuring uniform distribution and regulatory compliance.

Modulators block harmful SorLA binding to increase extracellular GDNF, addressing underlying causes of mental disorders.

Peptide vaccines stimulate cytotoxic T cells via HLA class I and II molecules, eliminating glioblastoma recurrence while avoiding chemotherapy side effects.

Blue light triggers chimeric polypeptide oligomerization, enabling precise spatiotemporal control over neurodegenerative disease modeling.

Segmented tryptophan peptides combined with staged glucose release elevate plasma ratios to improve cognitive benefits without allergic reactions.

Co-administering glutathione peroxidase mimics with antipsychotics reduces oxidative stress and mitigates adverse side effects.

Transduced glial cells supply enzyme to cerebrospinal fluid, bypassing the blood-brain barrier to treat Hunter syndrome neurocognitive symptoms.

VEGF-C flow modulators expand meningeal lymphatic drainage capacity, resolving insufficient amyloid beta plaque clearance in neurological disease treatment.

Targeting VCAM-1 mitigates synapse loss and neurodegeneration to restore cognitive function.

Probiotic compositions modulate TLR4-dependent signaling to alleviate urinary tract infection pain while avoiding antimicrobial resistance.

Segmented zinc-charged peptides overcome poor gastrointestinal absorption of large proteins while inducing apoptosis in cancer cells and reducing Tau protein.

Porous manifold distributes reduced pressure through nerve conduit walls to guide tissue regeneration while minimizing immunogenic responses.

Activity-dependent promoters regulate BDNF expression in neurons, resolving the contradiction between targeted delivery and reliable treatment effectiveness.

Adeno-associated virus vectors deliver AADC genes to the putamen, increasing enzyme activity and reducing motor fluctuations without systemic side effects.

Viral vectors deliver HLA-F sequences to motor neurons, resolving toxicity from ALS astrocytes and delaying disease progression.

Neural stem cells stably express IGF-1 to overcome limited efficacy of subcutaneous delivery methods in ALS treatment.

Local vector-based expression of chloride channels enables sustained neuronal modulation with reduced systemic side effects and lower administration frequency.

An antibody specifically recognizing the extracellular domain of CLDN-5 enables targeted modulation of the blood-brain barrier.

Sodium bromide reduces repetitive behaviors and anxiety, addressing side effects of existing ASD medications.

Combines RNAi gene silencing with neurotrophic factor delivery to overcome inadequate prevention in Huntington's, Parkinson's, and Alzheimer's therapies.

Human adipose stem cells form spheres in media containing CORM-2 and N-acetyl-L-cysteine to maintain an undifferentiated state.

Chelating magnesium to L-serine improves blood-brain barrier permeability, resolving low intracellular uptake of inorganic salts.

Patsnap Eureka analyzes ASIC inhibitors that suppress seizure activity by targeting acid sensing ion channels.

Perispinal biologics bypass the blood-brain barrier via the vertebral venous system, delivering TNF antagonists to treat chronic brain injury.

A JULGI protein detecting composition binds guanine-quadruplex structures for diagnostic applications.

Dynorphin peptide analogues inhibit pain signaling pathways via selective opioid receptor binding to reduce side effects.

An extended release agent slows capsaicinoid delivery to reduce burning sensations while maintaining therapeutic efficacy.

Phage-selected human IgG1 antibodies block GM-CSF activity, eliminating immune reactions from non-human therapies.

Satralizumab blocks IL-6 receptor signaling to prevent MOGAD relapses, avoiding adverse effects of conventional immunosuppressive therapies.

Segmenting entacapone into sub-55-micrometer granules via fluidized bed processing resolves swallowing difficulties while maintaining content uniformity.

Foil-wrapped elongate chewing gum prevents evaporation and eliminates blister pack noise.

Selective substituted benzamide derivatives block MAO-B activity, preventing oxidative stress and addressing neurodegenerative disease progression.

Segmented peptides prevent KIBRA binding to PKMzeta, disrupting memory maintenance for treating anxiety and addiction.

Engineered cocaine esterase mutants hydrolyze cocaine into inactive metabolites to provide prolonged therapeutic protection.